Dermorphin

Dermorphin is a naturally occurring heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) isolated from the skin secretions of the South American tree frog Phyllomedusa sauvagei by Montecucchi et al. in 1981. It is among the most potent naturally occurring mu-opioid receptor (MOR) agonists characterised — with published potency estimates 30-40 times that of morphine in comparative binding and functional assays — and exhibits remarkable MOR selectivity with minimal delta-opioid receptor (DOR) or kappa-opioid receptor (KOR) activity.

The most scientifically remarkable feature of Dermorphin is the biosynthetically incorporated D-alanine at position 2 — one of the extremely rare examples of a D-amino acid in a vertebrate-derived biological peptide. Unlike the uniformly L-amino acid world of ribosomal protein synthesis, Dermorphin's D-Ala2 is generated post-translationally by a specific peptide isomerase enzyme that converts the L-Ala initially incorporated by the ribosome into D-Ala. Kreil et al. (FEBS Letters, 1983) established this through precursor mRNA analysis — the codon at position 2 encodes L-alanine, confirming that D-Ala arises through post-translational isomerisation rather than non-ribosomal synthesis. This makes Dermorphin a model system for studying the rare biology of biosynthetic D-amino acid incorporation, which is now known to occur in a small number of other organisms including molluscs and bacteria.

The pharmacological importance of D-Ala2 is dramatic and clearly established through structure-activity relationship research. Replacing D-Ala2 with L-Ala2 reduces MOR affinity approximately 1000-fold. This extraordinary potency dependence on a single stereochemical change (D→L at one residue) reveals the exquisite sensitivity of the MOR orthosteric binding pocket to pharmacophore geometry. The D-configuration positions the adjacent Phe3 aromatic ring in the precise spatial orientation required for productive engagement with hydrophobic subpockets in the MOR transmembrane bundle. Additionally, D-Ala2 provides resistance to aminopeptidase degradation at the Tyr1-D-Ala2 bond — contributing to Dermorphin's longer plasma half-life compared to L-amino acid opioid pentapeptides like enkephalins.

MOR research applications for Dermorphin include: competitive radioligand displacement assays using [3H]-DAMGO or [3H]-naloxone to characterise MOR binding affinity in brain membrane preparations or recombinant MOR-expressing cell membranes; functional GTPgammaS binding assays (measuring G-protein activation as a measure of GPCR functional activity); cAMP suppression assays via Gi coupling (MOR-HEK293 cells); electrophysiology examining GIRK channel activation (outward K+ current) and N-type calcium channel inhibition in dorsal root ganglion neurons; and selectivity profiling against DOR (using naltrindole as selective antagonist) and KOR (using nor-BNI as selective antagonist) to quantify MOR:DOR:KOR selectivity ratios.

Dermorphin's anti-doping research relevance arose from its 2012 detection in racehorses — its exceptional potency and protease resistance made it attractive as a clandestine analgesic. This context has driven development of sensitive LC-MS/MS detection methods for dermorphin in biological matrices, which serve as useful reference analytical methods for research quality verification.

MW: 801.88 g/mol. CAS: 77614-16-5. Molecular formula: C40H51N7O10. Contains tryptophan — protect from light. Reconstitute in bacteriostatic water at 1mg/mL. Store lyophilised at -20°C. For laboratory and analytical research purposes only.

Practical MOR research notes: for radioligand binding assays, include protease inhibitors in the assay buffer (bacitracin 0.1mg/mL, PMSF 0.1mM) to protect both Dermorphin and radiolabelled reference ligands from degradation during incubation. For selectivity confirmation, use MOR-selective antagonist CTOP or naloxonazine, DOR antagonist naltrindole, and KOR antagonist nor-BNI as parallel controls. Dermorphin's D-Ala2 provides aminopeptidase resistance — the Tyr1-D-Ala2 bond is not cleaved — extending research utility in serum-containing systems. MW: 801.88 g/mol. CAS: 77614-16-5. Contains tryptophan — protect from light. Reconstitute in bacteriostatic water at 1mg/mL. Store lyophilised at -20°C. For laboratory and analytical research purposes only.